Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FoCus: ALXN1840 vs SoC in Wilson Disease
NCT03403205Phase 3Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Feb 2018
- Primary completion
- Jun 2023
- Modality
- Classical Binding Small Molecules
- Countries
- 22
01
Overview
A Phase 3 trial of atn-224 in Wilson disease (WD), sponsored by Alexion Pharmaceuticals. Started Feb 2018; status: terminated.
02
Drugs
atn-224
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on NCT03403205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03403205.